S-adenosylhomocysteine (SAH)-Driven Low Methylation Potential describes a situation in which methylation capacity may be reduced not primarily because the body lacks methyl donors, but because SAH accumulates.

S-adenosylmethionine (SAM) is the major methyl donor used by many methyltransferase enzymes. After SAM donates a methyl group, it becomes SAH. SAH is then normally processed by adenosylhomocysteinase (AHCY), also known as S-adenosylhomocysteine hydrolase, into homocysteine and adenosine.

The important point is that SAH is not just a passive waste product. When SAH rises, it can act as a brake on methyltransferase reactions. This means that the body may have methyl donors available, but the effective ability to run methylation reactions may still be limited.

This is why the SAM/SAH ratio, meaning the S-adenosylmethionine/S-adenosylhomocysteine ratio, is often discussed as a marker of methylation potential. A low SAM/SAH ratio can reflect reduced methylation potential because SAM is low, because SAH is high, or because both are happening at the same time.

This pattern is especially relevant when a person has tried to “support methylation” and the response does not match the usual expectation.

They may have expected methylfolate, methyl-B12, S-adenosylmethionine as a supplement (SAMe), trimethylglycine (TMG), or a stronger B-complex to mean better energy, better mood, better focus, better detoxification, or better resilience.

Instead, they may experience something more confusing:

• more anxiety;
• more insomnia;
• more agitation;
• more irritability;
• more brain fog;
• poorer working memory;
• a wired-but-not-well feeling;
• an initial improvement followed by a crash;
• a sense that “methylation support” is pushing the system rather than supporting it.

This does not prove that elevated SAH is the cause of those reactions. But it explains why the simple model, “low methylation means more methyl donors,” may be incomplete.

The central question of this pattern is not only:

“Do I have enough methyl donors?”

It is also:

“Can the system clear the inhibitory byproduct of methylation reactions efficiently enough?”

The simplified flow is:

Methionine → SAM → methyl donation → SAH → homocysteine + adenosine

In many methylation discussions, attention goes to the first half of the pathway. That includes folate, vitamin B12, methionine, choline, betaine, and the production of SAM.

This pattern focuses on the second half of the pathway: what happens after methyl donation has already occurred.

The basic sequence is:

1. Methionine is converted into SAM.
2. SAM donates a methyl group to a methyltransferase reaction.
3. After donation, SAM becomes SAH.
4. SAH must be processed by adenosylhomocysteinase (AHCY).
5. AHCY connects SAH with homocysteine and adenosine.

If SAH is not cleared efficiently enough, methylation reactions may become harder to run. This is because SAH can compete with SAM at methyltransferase enzymes and inhibit methyltransferase activity.

This changes the way methylation support should be understood.

In a simple donor-deficiency model, the main question is:
“Is there enough input?”

In this pattern, the question becomes:
“What happens when input increases?”

A person may add methylfolate, methyl-B12, S-adenosylmethionine as a supplement (SAMe), trimethylglycine (TMG), or a B-complex. These may increase methylation input or alter methylation flow.

But if the downstream system is already struggling to process SAH, more input may not translate into better methylation output.

This can create a mismatch between theory and experience.

On paper, the person may appear to be doing the “right” methylation-supportive things. In lived experience, the body may respond as if the system is being pushed through a bottleneck.

This is why the pattern should not be reduced to “undermethylation.” It is more specific than that.

It is not simply low methyl groups.

It is low effective methylation potential in the context of SAH pressure.

Source grade A

This is the central logic of the pattern.

Methylation does not depend only on the availability of methyl donors. It also depends on whether methyltransferase reactions remain favorable after methyl donation has occurred.

SAH matters because it can inhibit many SAM-dependent methyltransferases. In other words, SAH can behave like a biochemical brake.

This means that a person may have some methyl donors available, and may even have normal or elevated SAM, while still having reduced effective methylation potential if SAH is also elevated.
This is why looking at SAM alone may be misleading.

A high SAM level may not be enough if SAH is also high.

A normal SAM level may not be enough if SAH is elevated.

A low SAM/SAH ratio may reflect a system where methylation reactions are less favorable, even if methyl donors are present.

The SAM/SAH ratio is important because it reflects the relationship between the methyl donor and the inhibitory byproduct. It is not only about how much “fuel” is available. It is also about whether the brake is being pressed.

This pattern can explain why a person may not feel better when they add methylation support.
If methylation input increases, more methyl groups may enter the system. But if SAH clearance is limited, the system may not feel more efficient. It may feel more pressured.

This can feel like:

• stimulation without stability;
• more drive but less calm;
• more mental speed but worse clarity;
• more energy but worse sleep;
• initial improvement followed by worsening;
• a sense that the system is being forced rather than supported.

This does not mean that methyl donors are always wrong. It means that methyl donors are not always the complete answer.

The issue is not only whether methyl groups are available.

The issue is whether methyltransferase reactions remain favorable when SAH pressure is high.

Why this block matters

This pattern protects against a common oversimplification:

“Low methylation potential means I need more methyl donors.”

Sometimes that may be true.

But in this pattern, the problem may be different:

The body may not be asking for more input.

It may be showing that the downstream part of the methylation cycle needs more careful interpretation.

Source grade A

This pattern cannot be identified from symptoms alone. It is a laboratory-based interpretation pattern.

Possible laboratory findings may include:

• elevated SAH;
• low SAM/SAH ratio;
• normal SAM with elevated SAH;
• low SAM with elevated SAH;
• elevated SAM with elevated SAH;
• elevated homocysteine with elevated SAH;
• normal homocysteine with elevated SAH;
• low homocysteine with elevated SAH;
• kidney-function concerns that may affect SAH handling;
• chronic inflammatory or chronic disease context.

The most important interpretive point is:

A normal or low homocysteine result does not necessarily rule out low methylation potential if SAH is elevated and the SAM/SAH ratio is reduced.

This is one of the reasons this pattern is often missed.

A person may be told that homocysteine looks “fine.” That may be true. But homocysteine is not the same marker as SAH, and it does not always show whether the inhibitory byproduct of methylation reactions is accumulating.

A broader interpretation may need to consider:

• SAH;
• SAM;
• SAM/SAH ratio;
• homocysteine;
• methionine;
• adenosine-related context when available;
• kidney function;
• liver context;
• inflammatory or chronic disease context;
• current supplements;
• current medications;
• protein intake;
• the person’s actual response to methyl donor support.

High SAH with low SAM/SAH ratio

This is the clearest version of the pattern. The methylation potential may be reduced because SAH is high relative to SAM.

The question becomes:

Is the bottleneck downstream of methyl donation?

Normal SAM with high SAH

This can look deceptively “not too bad” if SAM is viewed alone. But if SAH is high, the SAM/SAH ratio may still be reduced.

The question becomes:

Is SAM being neutralized by the inhibitory pressure of SAH?

Low SAM with high SAH

This may suggest a double pressure: not enough methyl donor reserve and too much inhibitory byproduct.

In this case, simply adding donors may or may not be tolerated, depending on why SAH is high and how the downstream pathway is handling the load.

The question becomes:

Is the system low in input and also congested after output?

High SAM with high SAH

This pattern may be particularly confusing. SAM may look adequate or elevated, but SAH is also elevated.

The ratio may still be unfavorable.

The question becomes:

Is methylation input high, but clearance after methyl donation insufficient?

High SAH with normal homocysteine

This is one of the most important educational combinations. It challenges the assumption that homocysteine alone captures methylation status.

The question becomes:

Has the person been reassured by homocysteine while SAH was never checked?

High SAH with low homocysteine

This needs especially careful interpretation. Low homocysteine may reflect several different situations. It can occur in different nutritional, protein-intake, sulfur-flow, or transsulfuration contexts. In a SAH-focused interpretation, it also raises the question of whether the SAH-to-homocysteine relationship is behaving as expected.

The question becomes:

Is low homocysteine being interpreted too simply?

Source grade
The laboratory logic is supported by Grade A and Grade B sources. Grade A supports the role of SAH and the SAM/SAH ratio in methylation capacity. Grade B supports the clinical relevance of SAH and SAM/SAH ratio as human biomarkers, including evidence that homocysteine may not tell the whole story.

Homocysteine is commonly used as a methylation-related marker. When homocysteine is high, people often think about folate, vitamin B12, vitamin B6, riboflavin, choline, betaine, and other nutrients involved in homocysteine metabolism.

That can be useful in the right context. But it is not the whole picture.

This pattern highlights a different problem:

Homocysteine may not fully reflect methylation potential when SAH is elevated.

There are four reasons this matters.

1. SAH is not the same as homocysteine

SAH sits upstream of homocysteine in the methylation cycle. It is formed after SAM-dependent methylation reactions. It is then processed into homocysteine and adenosine.

Because these markers are connected, people often assume that homocysteine tells the whole story. But connected does not mean identical.

Homocysteine may be high, normal, or low while SAH gives additional information.

2. SAH can directly interfere with methyltransferase activity

The reason SAH matters is not only that it is near homocysteine in the pathway. It matters because SAH can inhibit methyltransferase reactions.

This is why a person may have available methyl donors and still have low effective methylation potential.

The system may have input, but the output is constrained by the inhibitory product.

3. Lowering homocysteine does not necessarily lower SAH

This is one of the most important evidence points for this pattern.

In a human B-vitamin intervention study, B-vitamin supplementation lowered total homocysteine but did not significantly lower plasma S-adenosylhomocysteine, S-adenosylmethionine, or clearly improve the S-adenosylmethionine/S-adenosylhomocysteine ratio.

In practical educational terms, this means:

A lower homocysteine result does not automatically prove that SAH improved.

This helps explain why some people feel disappointed or confused after following a homocysteine-focused plan. The number may improve, but the person may not feel the expected change.

4. Low homocysteine is not automatically “perfect”

Low homocysteine can be interpreted too quickly.

In some people, low homocysteine may reflect efficient homocysteine clearance. In others, it may raise questions about protein intake, sulfur amino acid availability, transsulfuration flow, methylation flux, or the relationship between SAH, homocysteine, and adenosine.

Low homocysteine should not be automatically treated as a problem. But it should also not be automatically assumed to mean that methylation potential is optimal.

The question is context.

Is SAH known?

Is SAM known?

Is the SAM/SAH ratio known?

Is the person reacting poorly to methylation input?

Are kidney function and chronic disease context being considered?

Why this matters emotionally

This pattern can be validating because many people get stuck in a narrow interpretation.

They may hear:

“Your homocysteine is normal, so methylation is fine.”

But their experience may be:

“I tried methylation support and felt worse.”

“I feel overstimulated by supplements that are supposed to help.”

“I improved for a few days and then crashed.”

“I cannot tell whether I need more methyl donors or fewer.”

“My labs do not explain my reaction.”

This pattern does not say that SAH explains every reaction. It says that homocysteine alone may be too narrow a window.

Source grade
This section is supported by Grade B evidence showing that B vitamins can lower homocysteine without lowering SAH or clearly improving the SAM/SAH ratio. It is also supported by Grade B biomarker literature showing that SAH and SAM/SAH ratio may carry information beyond homocysteine alone.

It is important not to turn lived experience into a diagnosis.

Anxiety after methylfolate does not prove high SAH.

Insomnia after methyl-B12 does not prove high SAH.

A poor response to SAMe does not prove impaired AHCY function.

Brain fog after B vitamins does not prove low SAM/SAH ratio.

But these reactions are still meaningful.

They may suggest that the person’s system does not tolerate increased methylation input well. That is a valid reason to look more carefully at the broader pattern rather than assuming that the answer is simply a higher dose, a stronger formula, or more methyl donors.

Source grade
This section is Grade U. It reflects a lived-experience and hypothesis-generating layer. It is useful for understanding what people are trying to make sense of, but it does not prove mechanism or causality.

Methylfolate may be useful when folate-dependent remethylation is limited. However, some people feel worse with methylfolate, especially in forms or doses that are too activating for their current state.

Reported reactions may include:

• anxiety;
• irritability;
• insomnia;
• agitation;
• brain fog;
• muscle tension;
• emotional volatility;
• feeling overstimulated but not energized.

In this pattern, the question is not only:

“Was the methylfolate dose too low or too high?”

The deeper question is:

“Was the system ready to tolerate increased methylation flux?”

If methylation input increases but downstream SAH clearance remains constrained, more input may not feel supportive.

Methyl-B12 may support vitamin B12-dependent remethylation. But in sensitive individuals, methyl-B12 may feel activating.

Some people tolerate hydroxocobalamin or adenosylcobalamin differently, but this should not be generalized. The better-tolerated form depends on the individual, the reason for using B12, baseline status, genetics, medications, and the broader metabolic pattern.

The key point is:

B12 form matters, but B12 form alone may not explain everything.
A person may react not only to the B12 molecule, but also to the shift in methylation flow that follows.

SAMe can feel powerful because it directly increases availability of the major methyl donor.

Some people report that SAMe initially improves:

• mood;
• motivation;
• mental clarity;
• energy;
• emotional resilience.

But some also report that the benefit fades or turns into a different pattern:

• anxiety;
• insomnia;
• irritability;
• cognitive worsening;
• poor working memory;
• emotional intensity;
• feeling pushed rather than supported.

From the perspective of this pattern, SAMe requires special caution conceptually. If SAM input rises, and methylation reactions increase, the downstream product SAH may also become more relevant.

This does not mean SAMe is always harmful. It means SAMe is not automatically appropriate for every “low methylation” picture.

A person who feels “better, then worse” with SAMe may need a more careful interpretation than simply increasing the dose.

B-complex products can contain many active compounds at once:

• methylfolate;
• folic acid or folinic acid;
• methyl-B12;
• hydroxocobalamin;
• adenosylcobalamin;
• riboflavin;
• niacin or niacinamide;
• vitamin B6 or pyridoxal-5-phosphate;
• pantothenic acid;
• biotin;
• choline or inositol in some formulas.

This makes reactions difficult to interpret.

If a person feels worse after a B-complex, it may be unclear whether the issue was:

• methylfolate;
• methyl-B12;
• vitamin B6;
• niacin;
• dose;
• timing;
• combination effect;
• baseline deficiency;
• baseline excess;
• medication interaction;
• increased methylation flux;
• unrelated coincidence.

For sensitive people, broad formulas may create more confusion than clarity.

Lowering homocysteine may be appropriate in some contexts. But homocysteine-lowering does not automatically prove that SAH has improved.

This is one of the central lessons of this pattern.

A person may improve homocysteine and still have unresolved symptoms, unresolved methyl donor intolerance, or an unfavorable SAM/SAH ratio.

That does not mean lowering homocysteine was useless. It means that homocysteine is not the only marker that matters.

SAH accumulation can be discussed at several levels of evidence.

The strongest layer is biochemical. The more practical functional layer is more cautious and should be treated as hypothesis-generating unless supported by laboratory context.

SAH is produced after SAM-dependent methylation reactions.

SAH can inhibit methyltransferases.

The SAM/SAH ratio is used as an indicator of methylation potential.

AHCY catalyzes the reversible conversion of SAH into homocysteine and adenosine.

The kidney plays an important role in maintaining circulating SAH levels.

These points are the foundation of the pattern.

SAH may be more difficult to interpret in the presence of:

• reduced kidney function;
• chronic kidney disease;
• altered creatinine or estimated glomerular filtration rate;
• liver disease context;
• chronic inflammation;
• chronic illness;
• altered homocysteine metabolism;
• altered methionine metabolism;
• oxidative stress burden;
• medication effects;
• high supplement load;
• very high or very low protein intake;
• unusual responses to methyl donors.

This does not mean these factors always cause high SAH. It means they can change how the pattern should be interpreted.

Kidney function deserves special attention in this pattern.

Human physiology evidence suggests that the kidney is a major site of circulating SAH disposal. This means that SAH interpretation should not be separated from kidney context.

A person looking at SAH should not interpret it in isolation from markers such as creatinine, estimated glomerular filtration rate, urinary findings when relevant, hydration status, medications, and known kidney disease.

This is not because every elevated SAH means kidney disease. It is because kidney function can be part of the SAH story.

Adenosylhomocysteinase (AHCY), also known as S-adenosylhomocysteine hydrolase, is the enzyme that helps process S-adenosylhomocysteine (SAH) into homocysteine and adenosine. The same name, AHCY, is also used for the gene that encodes this enzyme.

This enzyme sits directly at the point where SAH clearance occurs. For that reason, AHCY biology is highly relevant to understanding why SAH can accumulate and why SAH clearance matters for methylation potential.

Pathogenic variants in the AHCY gene can cause rare disorders of methionine metabolism. These conditions are medically serious and are not the same as common functional methylation concerns.

This distinction is essential.

A rare AHCY-related disorder is not diagnosed from a consumer genetic report, a supplement reaction, or a vague symptom cluster.

Rare-disease literature is useful because it shows that impaired SAH handling can profoundly disrupt S-adenosylmethionine (SAM) and S-adenosylhomocysteine (SAH) biochemistry. But it should not be used to imply that common methyl donor intolerance equals AHCY deficiency.

The responsible interpretation is:

AHCY biology helps explain why SAH clearance matters.

It does not justify casually diagnosing AHCY deficiency.

Some people may experience problems when methylation input is increased faster than the downstream system can tolerate.

Potential input-increasing factors may include:

• SAMe;
• high-dose methylfolate;
• high-dose methyl-B12;
• strong B-complex formulas;
• TMG;
• high methionine intake;
• combinations of multiple methyl-supportive nutrients.

This does not mean these inputs are bad. They may be appropriate in other patterns. But in this pattern, the question is whether the system can handle the flow after methyl donation.

Choline, betaine, creatine, and phosphatidylcholine are often discussed in methylation because they influence methylation demand and alternate methylation pathways.

Creatine synthesis uses methyl groups. Phosphatidylcholine synthesis can use methylation-dependent pathways. Choline and betaine can support methylation through the betaine-homocysteine methyltransferase pathway.

In a SAH-driven pattern, these factors are not automatically “solutions.” They are context.

For example:

• low creatine intake or synthesis may increase methylation demand;
• choline/betaine status may influence methylation flow;
• adding TMG may shift homocysteine remethylation but may not directly resolve SAH accumulation;
• adding multiple methylation-supportive nutrients at once may make interpretation harder.

This is why this pattern should be approached as a systems question, not a single-supplement question.

AHCY connects SAH with homocysteine and adenosine. Because the reaction is reversible and connected to adenosine metabolism, adenosine context may matter conceptually.

This area should be handled cautiously. It is not usually part of routine methylation interpretation, and it should not be overclaimed.

Still, for educational purposes, it is helpful to remember:

SAH does not exist alone.

It sits at a junction between methylation, homocysteine, and adenosine biology.

In functional and nutritional interpretation, several hypotheses may be considered cautiously:

• SAH clearance may be limited relative to methylation input;
• methyl donor load may exceed downstream tolerance;
• SAMe may not fit every low-methylation picture;
• homocysteine may not be sufficient as a single methylation marker;
• choline, betaine, creatine, and phosphatidylcholine status may influence methylation demand;
• adenosine and homocysteine handling may affect the SAH reaction;
• kidney function may influence circulating SAH;
• chronic stress or chronic illness may change methylation demand and tolerance.

These hypotheses should not be treated as proven explanations for every symptom. They are interpretive possibilities that may help organize further investigation.

Source grade
This section includes Grade A biochemical evidence, Grade B human biomarker and kidney-context evidence, Grade C rare-disease and mechanistic extension evidence, and Grade U functional hypotheses.

This pattern is useful because it helps prevent one of the most common methylation mistakes:
treating every methylation problem as a methyl donor deficiency.

A responsible interpretation begins with questions, not assumptions.

Self-navigation questions

Do I know my SAH level, or only homocysteine?

Do I know my SAM level?

Do I know my SAM/SAH ratio?

Is homocysteine high, normal, or low?

If homocysteine is normal, has SAH actually been checked?

If homocysteine is low, is that being interpreted carefully rather than automatically assumed to be ideal?

Is SAM low, normal, or high?

Is SAH high enough to lower the SAM/SAH ratio?

Did methylfolate improve me, worsen me, or produce mixed effects?

Did methyl-B12 feel calming, neutral, or overstimulating?

Did SAMe help at first and then create anxiety, insomnia, irritability, or cognitive worsening?

Do broad B-complex formulas make it harder to understand my individual response?

Am I trying to force methylation by adding more input while ignoring downstream clearance?

Have kidney function, liver context, chronic inflammation, chronic disease, and medication effects been
considered?

Am I interpreting an actual lab pattern, a symptom pattern, a supplement reaction pattern, or all three together?

What is established biochemistry?

What is plausible interpretation?

What remains speculative?

How not to misuse this pattern

Do not use this pattern to self-diagnose from symptoms.

Do not assume that every negative reaction to methylfolate means high SAH.

Do not assume that every negative reaction to SAMe means impaired AHCY function.

Do not assume that normal homocysteine proves methylation is optimal.

Do not assume that low homocysteine is automatically good or bad.

Do not treat consumer genetic reports as proof of enzyme dysfunction.

Do not use rare AHCY deficiency literature to explain common supplement intolerance without appropriate medical context.

Do not turn this pattern into fear of all methyl donors.

The purpose of this pattern is not to create alarm. It is to create a better map.

Responsible conclusion

SAH-driven low methylation potential is not a label to apply casually. It is not a diagnosis based on symptoms. It is not a reason to fear all methyl donors.

It is a pattern that asks for a more complete view.

When SAH is elevated and the SAM/SAH ratio is low, the methylation question changes.

It is no longer only:

“Do I have enough methyl donors?”

It becomes:

“Is the system able to clear the inhibitory byproduct of methylation reactions efficiently enough?”

This pattern can be validating for people whose reactions do not fit standard methylation advice. It helps explain why “more methylation support” may not always feel supportive.

The goal is not to push the system harder.

The goal is to understand the bottleneck more accurately.

Evidence Grade A

Established biochemical mechanism
A1. Vizán P., Di Croce L., Aranda S. Functional and Pathological Roles of AHCY. Frontiers in Cell and Developmental Biology. 2021. DOI: 10.3389/fcell.2021.654344.

Use for: AHCY as the enzyme that catalyzes the reversible breakdown of SAH; SAH as a byproduct and potent inhibitor of methyltransferase activity; the role of AHCY in local transmethylation reactions.

Grade: A, strong mechanistic review.
This source supports the core mechanism of the pattern: SAH is produced after SAM-dependent methyltransferase reactions, AHCY breaks SAH into adenosine and homocysteine, and excess SAH can inhibit methyltransferase activity.

A2. Zhang J., Zheng Y. G. SAM/SAH Analogs as Versatile Tools for SAM-Dependent Methyltransferases. ACS Chemical Biology. 2016; 11(3):583–597. DOI: 10.1021/acschembio.5b00812.

Use for: SAH as a feedback inhibitor of SAM-dependent methyltransferases and its relevance to methyltransferase biochemistry.

Grade: A, established biochemical mechanism.
This source is useful for explaining why SAH is not just a passive byproduct, but can act as a methylation brake.

A3. Yi P., Melnyk S., Pogribna M., Pogribny I. P., Hine R. J., James S. J. Increase in Plasma Homocysteine Associated with Parallel Increases in Plasma S-Adenosylhomocysteine and Lymphocyte DNA Hypomethylation. Journal of Biological Chemistry. 2000; 275(38):29318–29323. DOI: 10.1074/jbc.M002725200.

Use for: the relationship between elevated homocysteine, increased SAH, and reduced DNA methylation in lymphocytes.

Grade: A, direct biochemical and human-cell methylation evidence.
This source supports the mechanistic link between SAH accumulation and methylation inhibition.

A4. Caudill M. A., Wang J. C., Melnyk S., Pogribna M., Jernigan S., Collins M. D., Santos-Guzman J., Swendseid M. E., Cogger E. A., James S. J. Intracellular S-Adenosylhomocysteine Concentrations Predict Global DNA Hypomethylation in Tissues of Methyl-Deficient Cystathionine β-Synthase Heterozygous Mice. Journal of Nutrition. 2001; 131(11):2811–2818. DOI: 10.1093/jn/131.11.2811.

Use for: SAH as a strong predictor of reduced methylation capacity in a methyl-deficient model.

Grade: A, foundational experimental methylation-capacity evidence.
This source supports the concept that SAH itself is important, not only SAM level.

A5. James S. J., Melnyk S., Pogribna M., Pogribny I. P., Caudill M. A. Elevation in S-Adenosylhomocysteine and DNA Hypomethylation: Potential Epigenetic Mechanism for Homocysteine-Related Pathology. Journal of Nutrition. 2002; 132(8):2361S–2366S. DOI: 10.1093/jn/132.8.2361S.

Use for: SAH as a metabolic indicator of methylation status and a possible mediator between homocysteine and DNA hypomethylation.

Grade: A, biochemical and epigenetic mechanism review.
This source supports the broader interpretation that elevated SAH can be relevant to methylation potential.


Evidence Grade B
Human biomarker and clinical-context evidence

B1. Green T. J., Skeaff C. M., McMahon J. A., Venn B. J., Williams S. M., Devlin A. M., Innis S. M. Homocysteine-lowering vitamins do not lower plasma S-adenosylhomocysteine in older people with elevated homocysteine concentrations. British Journal of Nutrition. 2010; 103(11):1629–1634. DOI: 10.1017/S0007114509993552.

Use for: the key point that B vitamins can lower homocysteine without lowering SAH, SAM, or clearly improving the SAM/SAH ratio.

Grade: B, human intervention study.
This is one of the most important sources for the section “Why Homocysteine Alone May Mislead.”

B2. Garibotto G., Valli A., Anderstam B., Eriksson M., Suliman M. E., Balbi M., Rollando D., Vigo E., Lindholm B. The kidney is the major site of S-adenosylhomocysteine disposal in humans. Kidney International. 2009; 76(3):293–296. DOI: 10.1038/ki.2009.117.

Use for: kidney function as an important context for interpreting SAH.

Grade: B, direct human physiology evidence.
This source supports the statement that kidney function should be considered when interpreting SAH.

B3. Kerins D. M., Koury M. J., Capdevila A., Rana S., Wagner C. Plasma S-adenosylhomocysteine is a more sensitive indicator of cardiovascular disease than plasma homocysteine. American Journal of Clinical Nutrition. 2001; 74(6):723–729. DOI: 10.1093/ajcn/74.6.723.

Use for: SAH as a human biomarker that may carry information beyond homocysteine alone in cardiovascular-risk context.

Grade: B, human observational biomarker study.
This source supports the idea that SAH can be clinically informative beyond homocysteine alone.

B4. Xiao J., You Y., Chen X., Tang Y., Chen Y., Liu Q., Liu Z., Ling W. Higher S-adenosylhomocysteine and lower ratio of S-adenosylmethionine to S-adenosylhomocysteine were more closely associated with increased risk of subclinical atherosclerosis than homocysteine. Frontiers in Nutrition. 2022; 9:918698. DOI: 10.3389/fnut.2022.918698.

Use for: human biomarker evidence that SAH and SAM/SAH ratio may be more informative than homocysteine alone in a vascular-risk setting.

Grade: B, human cross-sectional biomarker evidence, not causal.
This source supports the interpretive importance of measuring SAH and SAM/SAH ratio rather than relying on homocysteine alone.

B5. Mihara A. et al. Association of serum S-adenosylmethionine, S-adenosylhomocysteine, and their ratio with the risk of dementia and death in a community. Scientific Reports. 2022; 12:12427. DOI: 10.1038/s41598-022-16242-y.

Use for: cautious statement that SAM, SAH, and SAM/SAH ratio are being studied as human risk-associated biomarkers beyond homocysteine alone.

Grade: B, prospective observational cohort, not causal.
This source is useful for showing that SAM/SAH ratio is being studied in human outcome research, while avoiding causal claims.


Evidence Grade C
Rare-disease models, mechanistic extensions, and early applied evidence

C1. Barić I. et al. S-adenosylhomocysteine hydrolase deficiency in a human: A genetic disorder of methionine metabolism. Proceedings of the National Academy of Sciences. 2004; 101(12):4234–4239. DOI: 10.1073/pnas.0400658101.

Use for: rare-disease proof that impaired SAH hydrolase activity can profoundly disrupt methionine-cycle metabolites.

Grade: C, rare-disease evidence.
This source should not be used to imply that common supplement intolerance equals AHCY deficiency.

C2. Huang Y., Chang R., Abdenur J. E. The biochemical profile and dietary management in S-adenosylhomocysteine hydrolase deficiency. Molecular Genetics and Metabolism Reports. 2022; 32:100885. DOI: 10.1016/j.ymgmr.2022.100885.

Use for: rare-disease evidence showing that impaired SAH hydrolase function can produce marked abnormalities in SAM and SAH.

Grade: C, rare-disease case report and literature review.
This should not be generalized to common functional methylation patterns. It is useful only as biological illustration that impaired SAH handling can be significant.

C3. Pavičić I. et al. Effects of S-Adenosylhomocysteine Hydrolase Inhibition. International Journal of Molecular Sciences. 2023; 24(22):16102. DOI: 10.3390/ijms242216102.

Use for: mechanistic discussion of SAH hydrolase inhibition, SAM/SAH balance, and methylation disruption.

Grade: C, mechanistic and model-based evidence, not a clinical protocol source.
This source is useful for conceptual framing, but not for supplement recommendations.

C4. Stanhope S. C., Weake V. M. AHCY: A Metabolic Gatekeeper at the Interface of Methylation, Redox Balance, and Cellular Stress Response. Journal of Biological Chemistry. 2026. DOI: 10.1016/j.jbc.2026.111220.

Use for: updated mechanistic framing of AHCY as linking SAH turnover, methylation capacity, adenosine/homocysteine flux, redox balance, chromatin regulation, and stress response.

Grade: C, recent mechanistic review.
Useful for conceptual framing, not for intervention claims.


Evidence Grade U
Lived-experience and hypothesis layer

U1. User-reported methyl donor intolerance patterns

Use for: understanding why people search for explanations when methylfolate, methyl-B12, SAMe, or B-complex formulas produce anxiety, insomnia, agitation, brain fog, irritability, or a wired-but-not-well state.

Grade: U, lived-experience layer only.
This does not prove that SAH is the cause.

U2. “SAMe helps first, then worsens” patterns

Use for: describing the experience in which direct methyl donor input may feel beneficial initially, then become poorly tolerated.

Grade: U, hypothesis-generating only.
This does not prove impaired SAH clearance or AHCY dysfunction.

U3. Normal homocysteine with unresolved methylation concerns

Use for: explaining why homocysteine-only interpretation can feel incomplete to readers whose broader experience does not fit the lab reassurance.

Grade: U, educational framing only.
This should be paired with Grade A and Grade B evidence, not used as causal evidence.

U4. Consumer genetic interpretation around AHCY

Use for: explaining why people may search for AHCY, SAHH, or SAH-clearance explanations after seeing genetic reports.

Grade: U, not diagnostic.
SNP reports alone should not be treated as evidence of impaired SAH clearance.

U5. Functional hypotheses involving choline, betaine, creatine, phosphatidylcholine, adenosine, histamine overlap, copper, or NAD-related context

Use for: cautious exploratory discussion of possible contributing factors or adjacent systems.

Grade: U unless supported by direct laboratory and clinical context.
These hypotheses should not be presented as established mechanisms for symptoms.